Efruxifermin
Akero Therapeutics Stock Skyrockets as Phase 2b MASH Trial Yields Groundbreaking Results
Akero Therapeutics, MASH, Efruxifermin, Phase 2b SYMMETRY Study, Stock Price, Transformational Data
Akero Reinforces Phase III FGF21 Analog Candidate with Enhanced Fibrosis Response Rates in MASH Data Update
Akero Therapeutics, FGF21 Analog, efruxifermin (EFX), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Phase IIb HARMONY Study, Fibrosis Response Rate, 96 Weeks, Statistically Significant Improvements